Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

AB SCIEX Announces Immunosuppressants Kit for Use by Doctors in Europe to Help Care for Organ Transplant Patients

Published: Friday, April 04, 2014
Last Updated: Friday, April 04, 2014
Bookmark and Share
The SCIEX IVD-MS™ Immunosuppressants kit is designed to give clinicians fast, accurate information about the level of immunosuppressant drug circulating in a patient’s body.

Every organ transplant patient in the world faces the potential danger of his/her body rejecting a new organ, such as a heart, kidney or liver.  Immunosuppressant drugs are required to help prevent rejection.  To help improve the monitoring of this life-saving drug therapy, AB Sciex Pte. Ltd. today announced an immunosuppressants kit for use by European doctors and hospitals.*  

Too little immunosuppressant could result in the body’s rejection of the new organ.  Too much could lead to toxic side-effects for the person.  Periodic monitoring of these patients, who usually have to take immunosuppressant drugs for the rest of their lives, is critically important. 

“AB Sciex is working to ensure the best in patient outcomes,” said Rainer Blair, President of AB Sciex.  “By making it easier for doctors and clinical laboratories to adopt this assay for immunosuppressant drug monitoring, we are able to improve the results that so directly impact patients’ lives.  Our new immunosuppressants kit will help deliver high quality, medical-related information that can help save lives.”

The SCIEX IVD-MS™ Immunosuppressants kit will work with the AB Sciex IVD-MS™ Analyzer, which is available for use in certain European countries.  Together, the kit and the analyzer will create a complete diagnostic solution for European hospitals and clinical laboratories, enabling simultaneous accurate quantitation of cyclosporine A, tacrolimus, sirolimus and everolimus in whole blood.  

AB Sciex has emerged as the new go-to provider of IVD kits in Europe for in vitro diagnostic purposes. The immunosuppressants kit, which is expected to ship in Europe in Q2, joins the company’s family of IVD kits in Europe.* Other kits include vitamin D analysis as well as an upcoming newborn screening kit, which was announced in a separate news release today.  

The technology used to perform this testing is mass spectrometry technology, which is an advanced analytical technique used for decades in the pharmaceutical industry, biomedical research and clinical research.  The benefits of this technology for customers include reliable results, comprehensive detection of compounds and metabolites, and fast, accurate quantitative measurement.  AB Sciex is a leader in transitioning clinical assays onto mass spectrometry.

AB Sciex is showcasing its immunosuppressants assay in its booth at Analytica this week in Munich, Germany.  Clinical experts from AB Sciex will also be on hand to answer questions about the company’s other IVD kits.  The clinical solutions will also be on display inside the Masstastic Voyage mobile laboratory parked at Analytica.  

*Will only be available in Europe, but not in every EU country. Contact a local AB SCIEX representative for more information. 

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AB SCIEX Wins New Product Innovation Award in Asia Pacific
The award recognizes the company’s continued innovation in the mass spectrometry industry and a number of new products introduced into the market in recent years.
Thursday, October 30, 2014
AB SCIEX Receives Frost & Sullivan Award
AB SCIEX has been awarded the 2013 Global Market Share Leadership Award for Mass Spectrometry from Frost & Sullivan.
Thursday, September 12, 2013
AB SCIEX Announces In Vitro Diagnostic Devices CE Marked for Europe
AB SCIEX launches the 3200MD CE-IVDD series for general in vitro diagnostic use in Europe.
Tuesday, May 21, 2013
AB SCIEX Achieves ISO 13485 Certification for Manufacturing of LC/MS Systems
This ISO certification is often considered a first step toward complying with European regulatory requirements for a device to be cleared for use in the clinic.
Monday, February 27, 2012
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos